Welcome to our dedicated page for Paysign news (Ticker: PAYS), a resource for investors and traders seeking the latest updates and insights on Paysign stock.
Paysign Inc. (PAYS) delivers innovative prepaid card solutions and digital payment services for healthcare, corporate, and government sectors. This news hub provides investors with essential updates on the company’s financial performance and strategic direction.
Access real-time announcements including earnings reports, partnership developments, and product innovations. Our curated collection features regulatory filings, leadership changes, and market expansion updates critical for informed decision-making.
Discover comprehensive coverage of Paysign’s fintech advancements in patient affordability programs and integrated payment processing. Content spans merger activity, technology patents, and compliance updates, maintained for accuracy and relevance.
Bookmark this page for streamlined access to Paysign’s evolving financial narrative. Combine fundamental analysis with timely news to track the company’s position in competitive payment processing markets.
Paysign, Inc. (NASDAQ: PAYS) reported strong Q2 2024 financial results, with total revenues up 29.8% to $14.33 million compared to Q2 2023. The company saw significant growth in both its plasma and pharma patient affordability businesses. Net income improved to $697,000, or $0.01 per diluted share, from a net loss in the same period last year. Adjusted EBITDA increased 95.8% to $2.24 million.
Key highlights include:
- Plasma revenue up 12.6%, with 477 centers at quarter-end
- Pharma patient affordability revenue up 266.8%, with 61 active programs
- Gross profit margin increased to 52.9%, up 207 basis points
- Unrestricted cash of $31.29 million and zero debt
Based on strong performance, Paysign raised its full-year 2024 guidance, now expecting total revenues between $56.5-$58.5 million and adjusted EBITDA of $9.0-$10.0 million.
Paysign (NASDAQ: PAYS) will host its second quarter 2024 earnings call on July 31, 2024, at 5:00 p.m. Eastern time. The call will detail the company's recent financial performance, including earnings, revenue, and other key metrics. Participants in the U.S. can join via dial-in at 877.407.2988, while international participants can use +1.201.389.0923. A webcast of the call is available, and a replay can be accessed until October 29, 2024, by dialing 877.660.6853 or +1.201.612.7415, using Conference ID 13747519. Financial professionals wishing to ask questions must register by July 26, 2024, by emailing ir@paysign.com.
Paysign, a leading provider of prepaid card programs and digital banking services, is set to participate in the 2024 Maxim Fintech Virtual Symposium. The event, scheduled for June 25, 2024, will see Jeff Baker, Paysign's CFO, speaking about industry trends starting at 9:00 a.m. PDT (12:00 p.m. EDT). This symposium will feature companies from specialty finance, payments, and real estate sectors that leverage advanced technology. The event, along with its recorded replay, is exclusively available to institutions and M-Vest members. Interested parties can sign up for M-Vest membership to gain access.
Paysign, a leading provider of prepaid card programs, patient affordability services, digital banking, and payment processing, announced its participation in the 2024 iAccess Alpha Buyside Best Ideas Summer Conference. The event will take place on June 25-26, 2024. Jeff Baker, Paysign's CFO, will present at 2:30 p.m. EDT on June 25 and host one-on-one meetings on June 26. The presentation will be webcast and available for replay. Investors can register and find more details on the conference website.
Paysign, a leader in prepaid card programs and digital banking services, announced its participation in the Sidoti Small-Cap Virtual Investor Conference on June 12-13, 2024.
Chief Financial Officer Jeff Baker will be available for one-on-one and small group meetings with investors during the event.
Paysign, Inc. reported strong financial results for the first quarter of 2024. With total revenues up by 30% and adjusted EBITDA growing by 135%, the company demonstrated robust growth. The patient affordability business saw a significant 305% revenue increase, contributing to overall growth. The company remains optimistic about future growth prospects and is focused on sustainable revenue and earnings growth.
